Formulary guidance and transparency from P&T to point of care


Reality Check on Rheumatoid Arthritis (Immunology)

Market access for RA treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Increasing percentage of restricted lives for health exchange and medicare formularies
  • Class Trends: How biosimilar products will impact market access and prescribing
  • Key Findings: The significance of payer contracting and patient assistance programs in this disease area

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team.  Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.